EU panel backs J&J, Legend’s Carvykti for second-line multiple myeloma
EU panel backs J&J, Legend’s Carvykti for second-line multiple myeloma
EU panel backs J&J, Legend’s Carvykti for second-line multiple myeloma
Published: Feb 26, 2024
By Tristan Manalac
BioSpace
The European Medicines Agency has recommended expanding Johnson & Johnson and Legend Biotech’s CAR-T therapy Carvytki (ciltacabtagene autoleucel) for use as an earlier treatment in patients with relapsed or refractory multiple myeloma, Legend announced on Friday.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) supported moving Carvykti into the second-line setting, opening up its use in patients who had undergone at least one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent. To be eligible, patients need to have shown disease progression on their last therapy and must be refractory to lenalidomide.
Currently, Carvykti is approved in the EU to treat patients with at least three prior lines of therapy, whose disease has worsened since the last treatment.
The CHMP recommendation will now be reviewed by the European Commission, which will hand out the final regulatory verdict.
The recommendation is backed by data from J&J and Legend’s Phase III CARTITUDE-4 study, a randomized trial that compared Carvykti against standard chemotherapy regimens, including pomalidomide-bortezomib-dexamethasone or daratumumab-pomalidomide-dexamethasone. Participants in the late-stage trial received one to three prior lines of treatment.
In January 2023, the partners released interim findings from CARTITUDE-4, showing that Carvykti met its primary endpoint and elicited a significant improvement in progression-free survival. The companies at the time did not reveal specific data but said that the study had been unblinded per the recommendation of an independent data monitoring committee.
Data from CARTITUDE-4 leaked in April 2023, demonstrating that treated patients saw a 74% reduction in the risk of disease progression versus standard treatment. Carvykti also decreased the risk of death by 22% compared with chemo, though this was not statistically significant.
Jesús San Miguel, professor and senior consultant at the Center Clinica Universidad de Navarra in Spain, said in a statement that CARTITUDE-4 “demonstrated significant clinical benefit for patients who experience a relapse early in the treatment of their disease.”
San Miguel also called the CHMP’s recommendation an “important step toward making Carvykti available to more patients in Europe.” He has served as a consultant and advisor to Legend but has not been paid for any media work, according to the announcement.
The CHMP’s positive opinion come as J&J and Legend prepare to face the FDA’s Oncologic Drugs Advisory Committee, which will discuss the partners’ application to push Carvykti into an earlier line of treatment in the U.S. The meeting is set for March 15, 2024.
Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at [email protected] or [email protected].
Source: BioSpace
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: